Kicking off the “largest pharmaceutical investment in Germany since reunification” in 1990, a symbolic groundbreaking ceremony for a plant of the US pharmaceutical group Eli Lilly was held in Alzey, Rhineland-Palatinate.
The record was underlined by Chancellor Olaf Scholz in a message on the company plans to start production activities in 2027 with a workforce of one thousand employees without benefiting from state aid.
Among other things, in Germany Eli Lilly will also produce “Mounjaro”, an anti-diabetes drug with the active ingredient tirzepatide, the same contained in the “Zepbound” weight loss drug from the same American group, available in the United States since November and which experts predict it will be a great success, reports dpa
breaking latest news © Copyright ANSA